Zacks Research Issues Positive Outlook for SRPT Earnings

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) – Equities research analysts at Zacks Research raised their Q2 2025 earnings per share estimates for Sarepta Therapeutics in a report released on Monday, October 21st. Zacks Research analyst S. Ganoria now anticipates that the biotechnology company will earn $2.09 per share for the quarter, up from their prior estimate of $2.08. The consensus estimate for Sarepta Therapeutics’ current full-year earnings is $1.45 per share. Zacks Research also issued estimates for Sarepta Therapeutics’ Q3 2025 earnings at $2.10 EPS, Q4 2025 earnings at $2.18 EPS, FY2025 earnings at $8.17 EPS and Q1 2026 earnings at $2.80 EPS.

Sarepta Therapeutics (NASDAQ:SRPT) last announced its quarterly earnings results on Wednesday, August 7th. The biotechnology company reported $0.07 EPS for the quarter, beating the consensus estimate of $0.01 by $0.06. Sarepta Therapeutics had a return on equity of 5.32% and a net margin of 3.14%. The company had revenue of $362.90 million for the quarter, compared to the consensus estimate of $394.38 million. During the same quarter last year, the company posted ($0.27) earnings per share. The company’s revenue for the quarter was up 38.9% compared to the same quarter last year.

Several other equities research analysts have also recently weighed in on the company. Jefferies Financial Group initiated coverage on Sarepta Therapeutics in a research report on Monday. They issued a “buy” rating and a $165.00 price objective for the company. Citigroup cut their price objective on Sarepta Therapeutics from $176.00 to $160.00 and set a “neutral” rating for the company in a report on Thursday, August 8th. William Blair upgraded Sarepta Therapeutics to a “strong-buy” rating in a research note on Friday, August 30th. Cantor Fitzgerald restated a “neutral” rating and issued a $152.00 target price on shares of Sarepta Therapeutics in a research note on Friday, September 20th. Finally, Royal Bank of Canada reiterated an “outperform” rating and issued a $182.00 price objective on shares of Sarepta Therapeutics in a research report on Monday. Two analysts have rated the stock with a hold rating, eighteen have issued a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $182.95.

Sarepta Therapeutics Stock Up 1.1 %

SRPT opened at $129.88 on Wednesday. Sarepta Therapeutics has a 1-year low of $55.25 and a 1-year high of $173.25. The company has a current ratio of 3.90, a quick ratio of 3.19 and a debt-to-equity ratio of 1.05. The stock has a market capitalization of $12.28 billion, a price-to-earnings ratio of 1,180.73 and a beta of 0.82. The business has a 50 day moving average of $128.87 and a 200-day moving average of $132.42.

Institutional Investors Weigh In On Sarepta Therapeutics

Institutional investors have recently bought and sold shares of the company. Nordea Investment Management AB increased its position in shares of Sarepta Therapeutics by 120.6% during the 1st quarter. Nordea Investment Management AB now owns 61,657 shares of the biotechnology company’s stock worth $8,004,000 after purchasing an additional 33,711 shares during the last quarter. Fifth Third Wealth Advisors LLC acquired a new position in shares of Sarepta Therapeutics during the 2nd quarter worth approximately $607,000. Teachers Retirement System of The State of Kentucky acquired a new position in shares of Sarepta Therapeutics during the 2nd quarter worth approximately $4,771,000. Securian Asset Management Inc. acquired a new position in shares of Sarepta Therapeutics during the 2nd quarter worth approximately $1,187,000. Finally, Natixis Advisors LLC acquired a new position in shares of Sarepta Therapeutics during the 2nd quarter worth approximately $1,918,000. Institutional investors own 86.68% of the company’s stock.

Insider Activity

In other Sarepta Therapeutics news, Director Michael Andrew Chambers acquired 37,038 shares of the business’s stock in a transaction dated Friday, August 16th. The shares were acquired at an average price of $133.80 per share, for a total transaction of $4,955,684.40. Following the acquisition, the director now directly owns 284,034 shares of the company’s stock, valued at approximately $38,003,749.20. This trade represents a 0.00 % increase in their position. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In other Sarepta Therapeutics news, CFO Ian Michael Estepan sold 5,985 shares of the business’s stock in a transaction that occurred on Friday, August 30th. The stock was sold at an average price of $137.36, for a total value of $822,099.60. Following the sale, the chief financial officer now owns 33,946 shares in the company, valued at approximately $4,662,822.56. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Michael Andrew Chambers bought 37,038 shares of the business’s stock in a transaction on Friday, August 16th. The stock was purchased at an average price of $133.80 per share, for a total transaction of $4,955,684.40. Following the purchase, the director now directly owns 284,034 shares in the company, valued at approximately $38,003,749.20. This represents a 0.00 % increase in their position. The disclosure for this purchase can be found here. 7.70% of the stock is currently owned by company insiders.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.